Proliferative vitreoretinopathy: Pathobiology and therapeutic targets

Seminars in Ophthalmology

Volumn 24, Issue 2, 2009, Pages 62-69

  Leiderman, Yannek I ^a,b   Miller, Joan W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Intercellular signaling peptides and proteins; Proliferative etiology physiopathology therapy; Retinal detachment; Vitreoretinopathy

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; SIGNAL PEPTIDE;

CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; FIBROBLAST; GLIA CELL; HISTOPATHOLOGY; HUMAN; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VITREORETINOPATHY; ANIMAL; METABOLISM; RETINA DETACHMENT;

ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RETINAL DETACHMENT; VITREORETINOPATHY, PROLIFERATIVE;

EID: 66149150641     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530902800082     Document Type: Review

References (88)

1. Gonin J. The treatment of detached retina by searing the retinal tears. Arch Ophthalmol 1930;4:621-625.
2. Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: A pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 1971;75:813-820.
3. D'Amico DJ. Clinical practice. Primary retinal detachment. N Engl J Med 2008; 359:2346-2354.
4. Charles S, Calzada J, Wood B. Vitreous Microsurgery, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2007; 231.
5. The SPR StudyGroup.View2:The caseforprimaryvitrectomy. Br J Ophthalmol 2003; 87:784-787.
6. Heimann H, Bartz-Schmidt KU, Bornfeld N, Weiss C, Hilgers RD, Foerster MH. Scleral buckling versus primary vitrectomy inrhegmatogenousretinal detachment:Aprospective randomized multicenter clinical study. Ophthalmology 2007;114:2142- 2154.
7. Campochiaro PA. Pathogenic mechanisms in proliferative vit-reoretinopathy. Arch Ophthalmol 1997;115:237-241.
8. Charteris DG. Proliferative vitreoretinopathy: Pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 1995;79:953-960.
9. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye 2002;16:369-374.
10. Kim IK, Arroyo JG. Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clin North Am 2002;15:81-86.
11. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-2617.
12. Stichel CC, Muller HW. The CNS lesion scar: New vistas on an old regeneration barrier. Cell Tissue Res 1998;294:1-9.
13. Fitch MT, Silver J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp Neurol 2008;209:294-301.
14. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 1991;112:159-165.
15. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983;90:121-125.
16. Charteris DG, Downie J, Aylward GW, Sethi C, Luthert P. In-traretinal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 2007;245:93- 100.
17. Clarkson JG, Green WR, Massof D. A histopathologic review of 168 cases of preretinal membrane. Am J Ophthalmol 1977;84:1- 17.
18. Kampik A, Kenyon KR, Michels RG, Green WR, de la Cruz ZC. Epiretinal and vitreous membranes. Comparative study of 56 cases. Arch Ophthalmol 1981;99:1445-1454.
19. Schwartz D, de la Cruz ZC, Green WR, Michels RG. Proliferative vitreoretinopathy. Ultrastructural study of 20 retroretinal membranes removed by vitreous surgery. Retina 1988;8:275- 281.
20. Wilkes SR, Mansour AM, Green WR. Proliferative vitreo-retinopathy. Histopathology of retroretinal membranes. Retina 1987;7:94-101.
21. Alberts B. Molecular Biology of the Cell, 4th ed. New York: Garland Science, 2002.
22. Hiscott PS, Grierson I, McLeod D. Retinal pigment epithelial cellsinepiretinal membranes:Animmunohistochemical study. Br J Ophthalmol 1984;68:708-715.
23. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: A pathological perspective. J Neuroinflammation 2004;1:14.
24. Stichel-Gunkel CC. The role of microenvironment in axonal regeneration. Influences of lesion-induced changes and glial implants on the regeneration of the postcommissural fornix. Adv Anat Embryol Cell Biol 1997;137:I-VII, 1-81.
25. Jerdan JA, Pepose JS, Michels RG, Hayashi H, de Bustros S, Sebag M, Glaser BM. Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 1989;96:801- 810.
26. Morino I, Hiscott P, McKechnie N, Grierson I. Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Br J Ophthalmol 1990;74:393-399.
27. Mitamura Y, Takeuchi S, Ohtsuka K, Matsuda A, Yamamoto T, Yamamoto S, Hiraiwa N, Kusakabe M. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy. Ophthalmologica 2003;217:422-425.
28. Hagedorn M, Esser P, Wiedemann P, Heimann K. Tenascin and decorin in epiretinal membranes of proliferative vitreo-retinopathy and proliferative diabetic retinopathy. Ger J Ophthalmol 1993;2:28-31.
29. Hiscott P, Hagan S, Heathcote L, Sheridan CM, Groenewald CP, Grierson I, Wong D, Paraoan L. Pathobiology of epiretinal and subretinal membranes: Possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC). Eye 2002;16:393-403.
30. Sheridan CM, Magee RM, Hiscott PS, Hagan S, Wong DH, Mc-Galliard JN, Grierson I. The role of matricellular proteins thrombospondin-1 and osteonectin during RPE cell migration in proliferative vitreoretinopathy. Curr Eye Res 2002;25:279-285.
31. David S, Ness R. Heterogeneity of reactive astrocytes. In: Fedoroff S, ed. Biology and Pathology of Astrocyte-neuron Interactions. New York: Plenum Press, 1993.
32. Fernaud-Espinosa I, Nieto-Sampedro M, Bovolenta P. Differential activation of microglia and astrocytes in aniso- and isomorphic gliotic tissue. Glia 1993;8:277-291.
33. Hatten ME, Liem RK, Shelanski ML, Mason CA. Astroglia in CNS injury. Glia 1991;4:233-243.
34. Jonas JB, Knorr HL, Budde WM. Prognostic factors in ocular injuries caused by intraocular or retrobulbar foreign bodies. Ophthalmology 2000;107:823-828.
35. Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui JZ, Kimura H, Hinton DR, Ryan SJ. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 1997;104:1166-1173.
36. Hiscott PS, Grierson I, Trombetta CJ, Rahi AH, Marshall J, McLeod D. Retinal and epiretinal glia-An immunohistochemical study. Br J Ophthalmol 1984;68:698-707.
37. Vinores SA, Van Niel E, Kim HJ, Campochiaro PA. Simultaneous expression of keratin and glial fibrillary acidic protein by the same cells in epiretinal membranes. Invest Ophthalmol Vis Sci 1992;33:3361-3366.
38. Frayer WC. Reactivity of the retinal pigment epithelium: An experimental and histopathologic study. Trans Am Ophthalmol Soc 1966;64:586-643.
39. Mandelcorn MS, Machemer R, Fineberg E, Hersch SB. Proliferation and metaplasia of intravitreal retinal pigment epithelium cell autotransplants. Am J Ophthalmol 1975;80:227-237.
40. Elner SG, Elner VM, Kindzelskii AL, Horino K, Davis HR, Todd RF, 3rd, Glagov S, Petty HR. Human RPE cell lysis of extracellular matrix: Functional urokinase plasminogen activator receptor (uPAR), collagenase and elastase. Exp Eye Res 2003;76:585-595.
41. Glaser BM, Vidaurri-Leal J, Michels RG, Campochiaro PA. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology 1993;100:466-470.
42. Campochiaro PA, Kaden IH, Vidaurri-Leal J, Glaser BM. Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. Arch Ophthalmol 1985;103:434-436.
43. Cowley M, Conway BP, Campochiaro PA, Kaiser D, Gaskin H. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol 1989;107:1147-1151.
44. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: Neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 1993;90:1526-1530.
45. Ogata N, Tombran-Tink J, Nishikawa M, Nishimura T, Mitsuma Y, Sakamoto T, Matsumura M. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001;132:378-382.
46. Ogata N, Wang L, Jo N, Tombran-Tink J, Takahashi K, Mrazek D, Matsumura M. Pigment epithelium derived factor as a neuroprotective agent against ischemic retinal injury. Curr Eye Res 2001;22:245-252.
47. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999;285:245-248.
48. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: Role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994;6:341-360.
49. Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC. Cytokines in proliferative vitreoretinopathy. Eye 1991;5 (Pt 6):686-693.
50. Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 1994;13:791-798.
51. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995;181:1205-1210.
52. Van Zee KJ, KohnoT,FischerE, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-4849.
53. Sippy BD, Hofman FM, Wright AD, He S, Ryan SJ, Hinton DR. Soluble tumor necrosis factor receptors are present in human vitreous and shed by retinal pigment epithelial cells. Exp Eye Res 1996;63:311-317.
54. Dopp JM, Mackenzie-Graham A, Otero GC, Merrill JE. Differential expression, cytokine modulation, and specific functions of type-1 and type-2 tumor necrosis factor receptors in rat glia. J Neuroimmunol 1997;75:104-112.
55. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 2001;42:1586-1591.
56. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989;169:1485-1490.
57. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of MCP-1 in endothelial cell tight junction 'opening': Signaling via Rho and Rho kinase. J Cell Sci 2003;116:4615-4628.
58. Kalehua AN, Nagel JE, Whelchel LM, Gides JJ, Pyle RS, Smith RJ, Kusiak JW, Taub DD. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res 2004;297:197-211.
59. Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 2003;85:1299-1311.
60. Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med 2003;9:781-788.
61. Nakazawa T, Hisatomi T, Nakazawa C, Noda K, Maruyama K, She H, Matsubara A, Miyahara S, Nakao S, Yin Y, Benowitz L, Hafezi-Moghadam A, Miller JW. Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis. Proc Natl Acad Sci U S A 2007;104:2425-2430.
62. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045-1053.
63. Abu el-Asrar AM, Van Damme J, Put W, Veckeneer M, Dralands L, Billiau A, Missotten L. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997;123:599-606.
64. Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998;18:546-550.
65. Han QH, Hui YN, Du HJ, Zhang WJ, Ma JX, Wang SY. Migration of retinal pigment epithelial cells in vitro modulated by monocyte chemotactic protein-1: Enhancement and inhibition. Graefes Arch Clin Exp Ophthalmol 2001;239:531-538.
66. Campochiaro PA, Glaser BM. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol 1985;103:576-579.
67. Deuel TF. Polypeptide growth factors: Roles in normal and abnormal cell growth. Annu Rev Cell Biol 1987;3:443-492.
68. Harvey AK, Roberge F, Hjelmeland LM. Chemotaxis of rat retinal glia to growth factors found in repairing wounds. Invest Ophthalmol Vis Sci 1987;28:1092-1099.
69. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, Planck SR, Rosenbaum JT. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994;35:3649-3663.
70. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155-169.
71. Hart CE, Bowen-Pope DF. Platelet-derived growth factor receptor: Current views of the two-subunit model. J Invest Dermatol 1990;94:53S-57S.
72. Andrews A, Balciunaite E, Leong FL, Tallquist M, Soriano P, Refojo M, Kazlauskas A. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1999;40:2683-2689.
73. Ikuno Y, Kazlauskas A. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor. Invest Ophthalmol Vis Sci 2002;43:41-46.
74. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-245.
75. Seo MS, Okamoto N, Vinores MA, Vinores SA, Hackett SF, Yamada H, Yamada E, Derevjanik NL, LaRochelle W, Zack DJ, Campochiaro PA. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol 2000;157:995-1005.
76. Saishin Y, Takahashi K, Seo MS, Melia M, Campochiaro PA. The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Invest Ophthalmol Vis Sci 2003;44:3656-3662.
77. Yamada H, Yamada E, Ando A, Seo MS, Esumi N, Okamoto N, Vinores M, LaRochelle W, Zack DJ, Campochiaro PA. Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. Am J Pathol 2000;156:477- 487.
78. Mori K, Gehlbach P, Ando A, Dyer G, Lipinsky E, Chaudhry AG, Hackett SF, Campochiaro PA. Retina-specific expression of PDGF-B versus PDGF-A: Vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci 2002;43:2001- 2006.
79. Ikuno Y, Leong FL, Kazlauskas A. PI3K and PLCgamma play a central role in experimental PVR. Invest Ophthalmol Vis Sci 2002;43:483-489.
80. Ikuno Y, Kazlauskas A. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci 2002;43:2406-2411.
81. Chen YS, Hackett SF, Schoenfeld CL, Vinores MA, Vinores SA, Campochiaro PA. Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol 1997;81:919- 926.
82. Schneeberger SA, Hjelmeland LM, Tucker RP, Morse LS. Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes. Am J Ophthalmol 1997;124:447-454.
83. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579- 1586.
84. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991.
85. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A 1993;90:7533-7537.
86. Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Male-caze F, Plouet J. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995;164:385- 394.
87. Dieudonne SC, La Heij EC, Diederen RM, Kessels AG, Liem AT, Kijlstra A, Hendrikse F. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Ophthalmic Res 2007;39:148-154.
88. Silver J. Special issue: Spinal cord regeneration and repair. Exp Neurol 2008;209:293.